Emerging Role of Vaccines in Glioblastoma Treatment
DOI:
https://doi.org/10.62051/42ynra44Keywords:
Glioblastoma; VLPs vaccine; mRNA vaccine; dendritic cells vaccine.Abstract
Glioblastoma is the most common primary intracranial malignant tumor, classified by the World Health Organization as a grade IV glioma of the central nervous system due to its high mortality, recurrence rate, and morbidity. This disease has difficulty to treat. Currently commonly used therapies, such as surgery, chemotherapy and radiotherapy, have poor prognosis. Therefore, new treatments are needed to control tumor progression and improve patient outcomes. After years of development, cancer vaccines have gradually become an important part of tumor immunotherapy, and they have shown a more rapid development trend in the current era. Cancer vaccines introduce tumor antigens, genes encoding tumor antigens, immune cells, and molecules into the body. Cancer vaccines activate specific immune responses that control tumor growth and ultimately clean it. In recent years, a number of research groups at home and abroad have explored the safety and feasibility of different types of therapeutic vaccines for the treatment of GBM according to the characteristics of GBM. This review introduces results, mechanism, safety and efficacy of virus-like particles (VLPs) vaccine, mRNA vaccine and dendritic cells (DC) vaccine. The feasibility of using these vaccines to treat GBM was discussed to provide reference for further research.
Downloads
References
[1] STUPP R, TAILLIBERT S, KANNER A, et al.Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma:arandomized clinical trial[J].JAMA,2017,318(23):2306-2316.
[2] Yuan Y, Gao F, Chang Y, et al. Advances of mRNA vaccine in tumor: a maze of opportunities and challenges[J]. Biomark Res, 2023, 11(1): 6.
[3] ANDREWS DW, JUDY KD, SCOTT CB,et al.Phase ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma[J].Clin Cancer Res,2021,27(7):1912-1922..
[4] SAGHI N, HOWＲA B, ZAKIEH S H, et al. Virus - like particles: Preparation, immunogenicity and their roles as nano vaccines and drug nanocarriers[J]. J Nanobiotechnology,2021,19(1)59.
[5] SUFFIAN I F B M, AL - JAMAL K T. Bioengineering of virus -like particles as dynamic nanocarriers for in vivo delivery and targeting to solid tumours[J/OL]. Adv Drug Deliv Ｒev,2022,180:114030. 2021-11-01[2022-11-19].
[6] MORRIS-LOVE J, ATWOOD W J. Complexities of JC polyomavirus receptor-dependent and independent mechanisms of infection[J]. Viruses,2022,14(6):1130.
[7] DELVALLEL, PINA-OVIEDO S. Human Polyomavirus JCPyVand its role in progressive multifocal leukoencephalopathy and oncogenesis[J/OL]. Front Oncol,2019,9:711.2019-08-08
[8] FINBLOOM J A, HAN K, AANEI I L, et al. Stable disk assemblies of a tobacco mosaic virus mutant as nanoscale Scaffolds for applications in drug delivery[J]. Bioconjug Chem,2016,27(10):2480-2485.
[9] WU W, SONNY C. H, ZACHAＲY M. C, et al. Genome-free viral capsids as multivalent carriers for taxol delivery [J /OL]. Angew Chem Int Ed Enl,2009,48(50):9493-9497.
[10] Beck JD, Reidenbach D, Salomon N, et al. mRNA therapeutics in cancer immunotherapy[J]. Mol Cancer, 2021,20(1): 69.
[11] Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics:developing a new class of drugs[J]. Nat Rev Drug Discov,2014, 13(10): 759-780.
[12] Karam M, Daoud G. mRNA vaccines: past, present, future[J]. Asian J Pharm Sci, 2022, 17(4): 491-522.
[13] Gote V, Bolla PK, Kommineni N, et al. A comprehensive review of mRNA vaccines[J]. Int J Mol Sci, 2023, 24(3):2700.
[14] Lorentzen CL, Haanen JB, Met Ö, et al. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment[J]. Lancet Oncol, 2022, 23(10): e450-458.
[15] Bernardo M, Tolstykh T, Zhang YA, et al. An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy [J]. Oncoimmunology, 2021, 10(1):1881268.
[16] Wculek SK,Cueto FJ,Mujal AM,et a1.Dendritic cells in cancer immunology and immunotherapy [J].Nat Rev Immu⁃nol,2020,20(1):7-24.
[17] Batich KA,Swartz AM,Sampson JH.Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma[J].Expert Opin Biol Ther,2015,15(1):79-94.
[18] Zhao J,Zhang Y,Chen Y,et al.A novel oral rabies vaccine enhances the immunogenicity through increasing dendritic cells activation and germinal center formation by expressing U-OMP19 in a mouse model [J].Emerg Microbes Infect,2021,10(1):913-928.
[19] Patel AP,Tirosh I,Trombetta JJ,et al.Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma[J].Science,2014,344(6190):1396-1401.
[20] Yu JS,Liu G,Ying H,et al.Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific,cytotoxic T-cells in patients with malignant glioma[J].Cancer Res,2004,64(14):4973-4979.
[21] Liau LM,Ashkan K,Tran DD,et al.First results on surviv⁃al from a large Phase 3 clinical trial of an autologous dendriticcell vaccine in newly diagnosed glioblastoma[J].J Transl Med,2018,16(1):142.
[22] O'Rourke DM,Nasrallah MP,Desai A,et a1.A singledose of peripherally infused EGFRvⅢ-directed CAR T cells medi⁃ates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma [J].Sci Transl Med,2017,9(399):eaaa0984.
[23] Tan L,Peng J,Liu P,et al.The efficacy of dendritic cell vaccine for newly diagnosed glioblastoma:a meta-analysis of randomized ontrolled studies[J].Clin Neuropharmacol,2021,44(6):216-221.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
